1. |
Lenis AT, Lec PM, Chamie K. Bladder cancer: a review. JAMA, 2020, 324(19): 1980-1991.
|
2. |
Funt SA, Rosenberg JE. Systemic, perioperative management of muscle-invasive bladder cancer and future horizons. Nat Rev Clin Oncol, 2017, 14(4): 221-234.
|
3. |
Edge SB, Compton CC. The American joint committee on cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol, 2010, 17(6): 1471-1474.
|
4. |
Alfred Witjes J, Lebret T, Compérat EM, et al. Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol, 2017, 71(3): 462-475.
|
5. |
Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med, 2003, 349(9): 859-866.
|
6. |
Hanna N, Trinh QD, Seisen T, et al. Effectiveness of neoadjuvant chemotherapy for muscle-invasive bladder cancer in the current real world setting in the USA. Eur Urol Oncol, 2018, 1(1): 83-90.
|
7. |
Necchi A, Joseph RW, Loriot Y, et al. Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase Ⅱ IMvigor210 study. Ann Oncol, 2017, 28(12): 3044-3050.
|
8. |
Powles T, Durán I, van der Heijden MS, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet, 2018, 391(10122): 748-757.
|
9. |
Witjes JA, Bruins HM, Cathomas R, et al. European Association of Urology guidelines on muscle-invasive and meta-static bladder cancer: summary of the 2020 guidelines. Eur Urol, 2021, 79(1): 82-104.
|
10. |
Flaig TW, Spiess PE, Agarwal N, et al. Bladder cancer, version 3. 2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw, 2020, 18(3): 329-354.
|
11. |
Basile G, Bandini M, Gibb EA, et al. Neoadjuvant pembrolizumab and radical cystectomy in patients with muscle-invasive urothelial bladder cancer: 3-year median follow-up update of PURE-01 Trial. Clin Cancer Res, 2022, 28(23): 5107-5114.
|
12. |
Powles T, Kockx M, Rodriguez-Vida A, et al. Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. Nat Med, 2019, 25(11): 1706-1714.
|
13. |
Szabados B, Kockx M, Assaf ZJ, et al. Final results of neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive urothelial cancer of the bladder. Eur Urol, 2022, 82(2): 212-222.
|
14. |
Gupta S, Gibb E, Sonpavde GP, et al. Biomarker analysis and updated clinical follow-up from BLASST-1 (Bladder cancer signal seeking trial) of nivolumab, gemcitabine, and cisplatin in patients with muscle-invasive bladder cancer (MIBC) undergoing cystectomy. J Clin Oncol, 2022, 40(Suppl 6): 528.
|
15. |
Kim H, Jeong BC, Hong J, et al. Neoadjuvant nivolumab plus gemcitabine/cisplatin chemotherapy in muscle-invasive urothelial carcinoma of the bladder. Cancer Res Treat, 2022, 55(2): 636-642.
|
16. |
Lin Tianxin, Li Kaiwen, Fan Jinhai, et al. Interim results from a multicenter clinical study of tislelizumab combined with gemcitabine and cisplatin as neoadjuvant therapy for patients with cT2-T4aN0M0 MIBC. J Clin Oncol, 2022, 40(Suppl 16): S4580.
|
17. |
Goubet AG, Lordello L, Alves Costa Silva C, et al. Escherichia coli-specific CXCL13-producing TFH are associated with clinical efficacy of neoadjuvant PD-1 blockade against muscle-invasive bladder cancer. Cancer Discov, 2022, 12(10): 2280-2307.
|
18. |
Wei XX, McGregor BA, Lee RJ, et al. Durvalumab as neoadjuvant therapy for muscle-invasive bladder cancer: preliminary results from the bladder cancer signal seeking trial (BLASST)-2. J Clin Oncol, 2020, 38(Suppl 6): 507.
|
19. |
van Dijk N, Gil-Jimenez A, Silina K, et al. Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial. Nat Med, 2020, 26(12): 1839-1844.
|
20. |
Van Dorp J, Suelmann BBM, Mehra N, et al. LBA31 high- vs low-dose pre-operative ipilimumab andnivolumab in locoregionally advanced urothelial cancer (NABUCCO cohort 2). Ann Oncol, 2021, 32(Suppl 5): S1305-S1306.
|
21. |
Gao J, Navai N, Alhalabi O, et al. Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. Nat Med, 2020, 26(12): 1845-1851.
|
22. |
Grande E, Guerrero F, Puente J, et al. DUTRENEO trial: a randomized phaseⅡtrial of Durvalumab and tremelimumab versus chemotherapy as a neoadjuvant approach to muscle-invasive urothelial bladder cancer (MIBC) patients (pts) prospectively selected by an interferon (INF)-gamma immune signature. J Clin Oncol, 2020, 38(Suppl 15): S5012.
|
23. |
Gupta S, Sonpavde G, Weight CJ, et al. Results from BLASST-1 (Blandder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in muscle-invasive bladder cancer (MIBC) undergoing cystectomy. J Clin Oncol, 2020, 38(Suppl 6): S439.
|
24. |
Martinez Chanza N, Carnot A, Barthelemy P, et al. 659MO Avelumab (A) as the basis of neoadjuvant chemotherapy (NAC) regimen in platinum eligible and ineligible patients (pts) with non-metastatic muscle invasive bladder cancer (NM-MIBC). Ann Oncol, 2021, 32(Suppl 5): S683.
|
25. |
Funt SA, Lattanzi M, Whiting K, et al. Neoadjuvant atezolizumab with gemcitabine and cisplatin in patients with muscle-invasive bladder cancer: a multicenter, single-arm, phaseⅡtrial. J Clin Oncol, 2022, 40(12): 1312-1322.
|
26. |
Cathomas R, Rothschild SI, Hayoz S, et al. Perioperative chemoimmunotherapy with durvalumab for muscle-invasive urothelial carcinoma: primary analysis of the single-arm phaseⅡtrial SAKK 06/17. J Clin Oncol, 2023, 41(33): 5131-5139.
|
27. |
Shen Y, Wen F, Zhang P, et al. Real-world study of chemotherapy plus immunotherapy versus chemotherapy alone as neoadjuvant treatment guided bladder-sparing therapy for localized muscle-invasive bladder cancer. J Clin Oncol, 2022, 40(Suppl 6): S499.
|
28. |
Shen Yali, Wen Feng, et al. HOPE-02: a phase 2, open-label study of neoadjuvant chemotherapy plus tislelizumab followed by radiotherapy based bladder-preserving treatment for high risk/locally advanced muscle invasive urothelial bladder cancer. ASCO-GU, 2023: abstract 516.
|
29. |
Hu J, Chen J, Ou Z, et al. Neoadjuvant immunotherapy, chemotherapy, and combination therapy in muscle-invasive bladder cancer: a multi-center real-world retrospective study. Cell Rep Med, 2022, 3(11): 100785.
|
30. |
Wen F, Lin T, Tan P, et al. 135O A multi-center phase Ⅰb/Ⅱ study of RC48-ADC combined with tislelizumab as neoadjuvant treatment in patients with HER2 positive locally advanced MIBC. Ann Oncol, 2022, 33(Suppl 9): S1485.
|
31. |
Petrylak DP, Flaig TW, Mar N, et al. Study EV-103 cohort H: antitumor activity of neoadjuvant treatment with enfortumab vedotin monotherapy in patients (pts) with muscle invasive bladder cancer (MIBC) who are cisplatin-ineligible. J Clin Oncol, 2022, 40(Suppl 6): S435.
|